Active Ingredients: Ciprofloxacin
Applies to ciprofloxacin: intravenous solution, oral powder for reconstitution, oral tablet, oral tablet extended release General The most common side effects from clinical trials of all formulations, doses, durations of therapy, and indications were nausea, diarrhea, abnormal liver function tests, vomiting, and rash.Metoclopramide significantly accelerates the absorption of oral ciprofloxacin resulting in shorter time to reach maximum plasma concentrations.
Ciprofloxacin was discontinued because of an adverse event in 1.
Some quinolones, including ciprofloxacin, have also been shown to interfere with the metabolism of caffeine. Histamine H 2 -receptor antagonists appear to have no significant effect on the bioavailability of ciprofloxacin.
Altered serum levels of phenytoin increased and decreased have been reported in patients receiving concomitant ciprofloxacin. Some quinolones, including ciprofloxacin, have been associated with transient elevations in serum creatinine in patients receiving cyclosporine concomitantly.
Quinolones, including ciprofloxacin, have been reported to enhance the effects of the oral anticoagulant warfarin or its derivatives.
Probenecid interferes with renal tubular secretion of ciprofloxacin and produces an increase in the level of ciprofloxacin in the serum.
This should be considered if patients are receiving both drugs concomitantly. This might increase the risk of methotrexate associated toxic reactions. Therefore, patients under methotrexate therapy should be carefully monitored when concomitant ciprofloxacin therapy is indicated.
Metoclopramide significantly accelerates the absorption of oral ciprofloxacin resulting in shorter time to reach maximum plasma concentrations.
No significant effect was observed on the bioavailability of ciprofloxacin. Non-steroidal anti-inflammatory drugs but not acetyl salicylic acid in combination of very high doses of quinolones have been shown to provoke convulsions in pre-clinical studies.
Results from photo co-carcinogenicity testing indicate that ciprofloxacin does not reduce the time to appearance of UV-induced skin tumors as compared to vehicle control. Hairless Skh-1 mice were exposed to UVA light for 3. The times to development of skin tumors ranged from 16-32 weeks in mice treated concomitantly with UVA and other quinolones.
The clinical significance of these findings to humans is unknown.